Ziccum-presentation och VD-intervju från Kapitalmarknadsdag nu tillgängliga

About Ziccum

Ziccum is developing LaminarPaceTM, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPaceTM uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.

About the mRNA field
The new mRNA technology, first implemented in the Covid mass vaccinations, has a become a game-changer in pharmaceutical development, generating multi-billion-dollar development efforts all over the global industry. Solving stability limitations and delivery challenges, as mRNA in LNP formulation is a very complex and delicate structure, would enable a cornerstone treatment across new indications, also targeting so called undruggable genes. A market forecast predicts the mRNA domain to grow to 59 BUSD by 2031 (1). However, existing methods for treatment, formulation or drying do not solve the limitations regarding stability nor fragility, and options for delivery are limited to injection currently.  (1) Straits Research, June 08, 2023